Gsk Plc (GSK.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Income taxes - deferred | 1,112,000 | 526,000 | 756,000 | 707,000 | 346,000 |
| Accounts receivable | -1,097,000 | 340,000 | -649,000 | -616,000 | -1,096,000 |
| Other Working Capital | -1,437,000 | 2,090,000 | -364,000 | 270,000 | 1,260,000 |
| Other Operating Activity | 9,163,000 | 3,598,000 | 7,025,000 | 7,042,000 | 7,442,000 |
| Operating Cash Flow | $7,741,000 | $6,554,000 | $6,768,000 | $7,403,000 | $7,952,000 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -1,324,000 | -1,334,000 | -1,286,000 | -997,000 | -1,029,000 |
| Net Acquisitions | -1,639,000 | 1,368,000 | 291,000 | -3,136,000 | 185,000 |
| Sale Of Investment | N/A | 21,000 | 72,000 | N/A | 18,000 |
| Purchase Sale Intangibles | -1,522,000 | -1,452,000 | -1,018,000 | -919,000 | -987,000 |
| Other Investing Activity | 367,000 | 299,000 | 358,000 | -3,524,000 | 808,000 |
| Investing Cash Flow | $-4,233,000 | $-1,229,000 | $-1,595,000 | $-8,772,000 | $-1,777,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 927,000 | -626,000 | -2,449,000 | -4,053,000 | -1,995,000 |
| Debt Issued | 1,979,000 | 1,075,000 | 223,000 | 1,025,000 | N/A |
| Debt Repayment | -1,400,000 | -1,615,000 | -144,000 | -1,594,000 | N/A |
| Common Stock Issued | 15,000 | 20,000 | 10,000 | 25,000 | 21,000 |
| Common Stock Repurchased | -1,377,000 | N/A | N/A | N/A | N/A |
| Dividend Paid | -2,564,000 | -2,444,000 | -2,247,000 | -3,467,000 | -3,999,000 |
| Other Financing Activity | -1,265,000 | -1,136,000 | -1,034,000 | 8,887,000 | -1,616,000 |
| Financing Cash Flow | $-3,685,000 | $-4,726,000 | $-5,641,000 | $823,000 | $-7,589,000 |
| Exchange Rate Effect | -19,000 | -54,000 | -99,000 | 152,000 | -29,000 |
| Beginning Cash Position | 3,403,000 | 2,858,000 | 3,425,000 | 3,819,000 | 5,262,000 |
| End Cash Position | 3,207,000 | 3,403,000 | 2,858,000 | 3,425,000 | 3,819,000 |
| Net Cash Flow | $-177,000 | $599,000 | $-468,000 | $-546,000 | $-1,414,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 7,741,000 | 6,554,000 | 6,768,000 | 7,403,000 | 7,952,000 |
| Capital Expenditure | -2,985,000 | -2,982,000 | -2,344,000 | -2,258,000 | -2,931,000 |
| Free Cash Flow | 4,756,000 | 3,572,000 | 4,424,000 | 5,145,000 | 5,021,000 |